Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 4/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | DAPK1 | P53355 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16202368 | 0.82 | RET (0.49) | RETADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL16375261 | 0.72 | UTS2R (0.34) | — | |
| SCHEMBL12913615 | 0.68 | DAPK1 (0.51) | ADORA3ADORA2AADORA2BADORA1DAPK1 | |
| SCHEMBL16375259 | 0.67 | SRC (0.44) | RET | |
| SCHEMBL15187503 | 0.66 | — | — | |
| SCHEMBL24458309 | 0.66 | ADORA2A (0.53) | RETADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22037128 | 0.66 | MEN1 (0.41) | RETADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL25388077 | 0.66 | RET (0.49) | RETADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL22102953 | 0.64 | KDM5B (0.30) | — | |
| SCHEMBL12913585 | 0.63 | ADORA2A (0.50) | ADORA3ADORA2AADORA2BADORA1DAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9458162-B2 | Cyclic molecules as bruton's tyrosine kinase inhibitors | NANJING ALLGEN PHARMA CO. LTD. (CN) | 2016-10-04 | — | — | US | disclosed |
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2015-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150011530-A1 | CYCLIC MOLECULES AS BRUTON'S TYROSINE KINASE INHIBITORS | ABL1, BTK, PRKACA | RET 354/4885ADORA3 4282/4885ADORA2A 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.